Showing 7121-7130 of 19322 results for "".
Clinical Stability Post-Tovorafenib in Pediatric Low-Grade Glioma: FIREFLY-1 Results
https://reachmd.com/programs/project-oncology/tovorafenib-clinical-stability-pediatric-low-grade-glioma/37195/What if clinical stability in pediatric low-grade glioma could be maintained after treatment ends? Emerging data from the phase 2 FIREFLY-1 trial suggest that tovorafenib may offer durable off-therapy disease control, even in the presence of radiographic changes. With a 53% objective response rate,Recapping the 2021 ACG Clinical Guidelines: What’s New in Colorectal Cancer Screening?
https://reachmd.com/programs/gi-insights/recapping-the-2021-acg-clinical-guidelines-whats-new-in-colorectal-cancer-screening/13011/With so many different colorectal cancer screening options available, which is best for your patients based on the latest guidelines?Family Planning Clinical Considerations for Patients with Multiple Sclerosis
https://reachmd.com/programs/neurofrontiers/family-planning-clinical-considerations-for-patients-with-multiple-sclerosis/18044/What family planning considerations should be made for our multiple sclerosis patients? Here’s what you need to know.Using AI to Predict MS Progression
https://reachmd.com/programs/neurofrontiers/using-ai-to-predict-ms-progression/26758/Tune in to hear key takeaways from a presentation at the 2024 ECTRIMS Congress that focused on the use of AI to predict MS progression.Evaluating Post-CDK4/6 Therapy in PIK3CA-Mutated Metastatic Breast Cancer
https://reachmd.com/programs/project-oncology/post-cdk46-therapy-pik3ca-mutated-metastatic-breast-cancer/36167/Real-world evidence is critical for guiding post-CDK4/6 treatment decisions in patients with PIK3CA-mutated metastatic breast cancer. That’s why a recent study presented at the 2025 San Antonio Breast Cancer Symposium analyzed treatment patterns, real-world outcomes, and resistance mechanisms followCases From the Real World: 91-Year-Old Patient With Wet AMD and a Submacular Hemorrhage
https://reachmd.com/programs/cme/Cases-From-the-Real-World-91-Year-Old-Patient-With-Wet-AMD-and-a-Submacular-Hemorrhage/33168/Hear how Drs. Danny Mammo and Ted Leng are using second-generation retinal agents to manage patients with PEDs from nAMD.Microglia Drive Neurodegeneration in Friedreich’s Ataxia
https://reachmd.com/programs/neurofrontiers/microglia-drive-neurodegeneration-in-friedreichs-ataxia/54668/Friedreich’s ataxia has long been viewed as a neuron-centric mitochondrial disorder, but emerging evidence highlights microglia as active drivers of neurodegeneration. In this AudioAbstract, Ryan Quigley explores study findings demonstrating how microglial dysfunction contributes to disease pathologBCMA mRNA CAR-T Shows Durable Benefit in MG
https://reachmd.com/programs/neurofrontiers/bcma-mrna-car-t-shows-durable-benefit-in-mg/51012/Cohort 9 of the Phase 2 EV-202 Trial: First-Line Enfortumab Vedotin Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
https://reachmd.com/clinical-practice/oncology-hematology/cohort-9-of-the-phase-2-ev-202-trial-first-line-enfortumab-vedotin-plus-pembrolizumab-in-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma/39779/In cohort 9 of EV-202, first-line enfortumab vedotin plus pembrolizumab showed promising and durable responses in patients with recurrent or metastatic HNSCC.Understanding and Treating Trauma in Pediatric Patients: Key Management Strategies
https://reachmd.com/programs/clinicians-roundtable/understanding-and-treating-trauma-in-pediatric-patients-key-management-strategies/37131/Childhood trauma can profoundly alter brain and behavioral development, making it essential to recognize how trauma differs from other diagnoses like ADHD. Ryan Quigley sits down with Drs. Heather Forkey and Wynne Morgan, who presented on this topic at the 2025 American Academy of Pediatrics Nationa